Global Musculoskeletal Disorders Therapeutics Market 2016-2020

Publisher Name :
Date: 31-Aug-2016
No. of pages: 120
Inquire Before Buying

Musculoskeletal disorders are the group of pain disorders or injuries that affect the body's joints, muscles, nerves, ligaments, tendons, and structures, all of which support the hands, legs, neck and back. The pain and discomfort vary with the severity of the condition. These disorders have a wide range of causes, but usually occur depending on the age, lifestyle, and occupation of an individual. Symptoms usually range from recurrent pain, stiffness, and swellings. X-rays and other medical imaging procedures may diagnose the condition. The treatment mainly depends on the severity of the condition. Apart from the drugs, physical therapy, and occupational therapy are also used to manage the condition.

The analysts forecast global musculoskeletal disorder therapeutics market to grow at a CAGR of 4.46% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global musculoskeletal disorder therapeutics market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded, generic, and off-label drugs used to treat musculoskeletal disorders including osteoarthritis, rheumatoid arthritis, osteoporosis, ankylosing spondylitis, psoriatic arthritis, and fibromyalgia.

The market is divided into the following segments based on geography:


  • Americas

  • APAC

  • EMEA


The report, Global Musculoskeletal Disorder Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors


  • AbbVie

  • Johnson & Johnson

  • Amgen

  • Pfizer

  • F. Hoffmann-La Roche

  • Eli Lilly


Other prominent vendors


  • 3SBio

  • AB Sciences

  • AbGenomics International

  • Ablynx

  • Adheron

  • Akron Molecules AG

  • Alder BioPharmaceuticals

  • Amgen Astellas BioPharma K.K. in Japan

  • Ampio Pharmaceuticals

  • Antares Medical Services

  • Astellas

  • AstraZeneca

  • Baxter

  • Biocad

  • Bioiberica

  • Boehringer Ingelheim

  • Bone Therapeutics

  • Can-Fite BioPharma

  • Celgene

  • Celltrion

  • Cellular Biomedicine

  • Cerapedics

  • ChemoCentryx

  • Chugai Pharmaceutical

  • Coherus Biosciences

  • Daiichi Sankyo

  • Dong-A ST

  • Edding Pharm

  • Eisai

  • Epirus

  • Eupraxia Pharmaceuticals

  • Flexion Therapeutics

  • Galapagos NV

  • Gedeon Richter

  • Gilead Sciences

  • GlaxoSmithKline

  • Histogenics

  • IBSA Institut Biochimique

  • iCeutica

  • Iltoo Pharma

  • Incyte

  • Innovative Med Concepts

  • Iroko Pharmaceuticals

  • ISTO Technologies

  • KaloBios Pharmaceuticals

  • KAN Research Institute

  • Kang Stem Biotech

  • Kitov Pharmaceuticals

  • Lexicon Pharmaceuticals

  • LG Life Sciences

  • MEDIPOST

  • Medivir

  • Merck

  • Mereo

  • Mesoblast

  • MOCHIDA PHARMACEUTICAL

  • MorphoSys

  • Morphotek

  • Mycenax

  • Neomed Institute

  • Novartis

  • Omeros

  • OrthoTrophix

  • Osteologix

  • OxyPharma

  • PFEnex

  • Philogen

  • PhytoHealth

  • Plexxikon

  • PLx Pharma

  • Protalex

  • Proximagen

  • Radius Health

  • Regeneron Pharmaceuticals

  • Samsung Bioepis

  • Samumed

  • Sandoz

  • Sanofi

  • SantoSolve AS

  • Steminent Biotherapeutics

  • Stempeutics Research

  • Taiwan Liposome Company

  • Takeda

  • Tarsa Therapeutics

  • Techfields Pharma

  • Tetec AG

  • TheraMAB

  • TiGenix

  • TissueGene

  • Tonix Pharmaceuticals

  • Translational Biosciences

  • UCB

  • Vericel

  • Vertex Pharmaceuticals

  • Vitaeris

  • Winston Laboratories

  • Zosano Pharma


Market driver


  • Tentative approval of advanced drugs

  • For a full, detailed list, view our report


Market challenge


  • Growing preference toward surgeries

  • For a full, detailed list, view our report


Market trend


  • Ongoing active clinical trials for biosimilars

  • For a full, detailed list, view our report


Key questions answered in this report


  • What will the market size be in 2020 and what will the growth rate be?

  • What are the key market trends?

  • What is driving this market?

  • What are the challenges to market growth?

  • Who are the key vendors in this market space?

  • What are the market opportunities and threats faced by the key vendors?

  • What are the strengths and weaknesses of the key vendors?

Global Musculoskeletal Disorders Therapeutics Market 2016-2020

Table of Contents

PART 01: Executive summary
Highlights

PART 02: Scope of the report
Market overview
Top-vendor offerings

PART 03: Market research methodology
Research methodology
Economic indicators

PART 04: Introduction
Key market highlights

PART 05: Pipeline portfolio

PART 06: Market landscape
Market overview
Market size and forecast
Five forces analysis

PART 07: Market segmentation by disease type
Rheumatoid arthritis
Osteoarthritis
Osteoporosis
Psoriatic arthritis
Ankylosing spondylitis
Fibromyalgia

PART 08: Global rheumatoid arthritis drugs market
Market overview

PART 09: Global osteoarthritis drugs market
Market overview

PART 10: Global osteoporosis drugs market
Market overview

PART 11: Global ankylosing spondylitis drugs market
Market overview

PART 12: Global psoriatic arthritis drugs market
Market overview

PART 13: Global fibromyalgia drugs market
Market overview

PART 14: Market segmentation by type of molecule
Biologics
Small molecules

PART 15: Market segmentation by route of administration
Parenteral
Topical
Oral

PART 16: Geographical segmentation
Global musculoskeletal disorder therapeutics market by geography 2015-2020
Musculoskeletal disorders therapeutics market in Americas
Musculoskeletal disorders therapeutics market in EMEA
Musculoskeletal disorders therapeutics market in APAC

PART 17: Market drivers
High growth potential of mAbs
Unmet needs of therapeutics
Tentative approval of advanced drugs
Technological advancements in medical imaging
Combination therapies

PART 18: Impact of drivers

PART 19: Market challenges
Non-adherence to treatment regimen
Growing preference toward surgeries
Multiple patent expiries

PART 20: Impact of drivers and challenges

PART 21: Market trends
Focus on regenerative medicines
Ongoing active clinical trials for biosimilars
Growing focus toward abuse-resistant novel drugs

PART 22: Vendor landscape
Competitive scenario

PART 23: Key vendor analysis
AbbVie
Johnson & Johnson
Amgen
Pfizer
F. Hoffmann-La Roche
Eli Lilly
Other prominent vendors

PART 24: Appendix
List of abbreviations

List of Exhibits

Exhibit 01: Product offerings
Exhibit 02: Key customer segments for musculoskeletal disorder therapeutics
Exhibit 03: Impact of biologics on various sectors
Exhibit 04: Pipeline portfolio: Global rheumatoid arthritis drugs market
Exhibit 05: Pipeline portfolio: Global osteoarthritis drugs market
Exhibit 06: Pipeline portfolio: Global osteoporosis drugs market
Exhibit 07: Pipeline portfolio: Global psoriatic arthritis drugs market
Exhibit 08: Pipeline portfolio: Global fibromyalgia drugs market
Exhibit 09: Pipeline portfolio: Global ankylosing spondylitis drugs market
Exhibit 10: Global musculoskeletal disorder therapeutics market 2015-2020 ($ billions)
Exhibit 11: Patient assistance programs offered by companies
Exhibit 12: CAM therapies for rheumatoid arthritis
Exhibit 13: Five forces analysis
Exhibit 14: Segmentation of global musculoskeletal disorder therapeutics market
Exhibit 15: Segmentation of global musculoskeletal disorder therapeutics market by revenue 2015
Exhibit 16: Opportunities in rheumatoid arthritis drugs industry
Exhibit 17: Global rheumatoid arthritis drugs market 2015-2020 ($ billions)
Exhibit 18: Unmet medical needs with current osteoarthritis treatments
Exhibit 19: Global osteoarthritis drugs market 2015-2020 ($ billions)
Exhibit 20: Global osteoporosis drugs market 2015-2020 ($ billions)
Exhibit 21: Global ankylosing spondylitis drugs market 2015-2020 ($ billions)
Exhibit 22: Global psoriatic arthritis drugs market 2015-2020 ($ billions)
Exhibit 23: Global fibromyalgia drugs market 2015-2020 ($ billions)
Exhibit 24: Segmentation of global musculoskeletal disorder therapeutics market by type of molecules 2015
Exhibit 25: Segmentation of global musculoskeletal disorder therapeutics market by ROA 2015
Exhibit 26: Global musculoskeletal disorder therapeutics market by geography 2015-2020
Exhibit 27: Global musculoskeletal disorder therapeutics market segmentation by geography 2015-2020 ($ billions)
Exhibit 28: Global share of musculoskeletal disorders therapeutics market by geography 2015
Exhibit 29: Global musculoskeletal disorder therapeutics market: Country analysis based on revenue and growth rate
Exhibit 30: Musculoskeletal disorders therapeutics market in Americas 2015-2020 ($ billions)
Exhibit 31: Musculoskeletal disorders therapeutics market in EMEA 2015-2020 ($ billions)
Exhibit 32: Musculoskeletal disorders therapeutics market in APAC 2015-2020 ($ billions)
Exhibit 33: Few of the late-stage mAbs under development for various musculoskeletal disorders
Exhibit 34: Impact of drivers
Exhibit 35: Approval and patent expiries of top selling biologics
Exhibit 36: Impact of drivers and challenges
Exhibit 37: Key vendors ranking 2015
Exhibit 38: Geographical presence of key vendors
Exhibit 39: Competitive scenario of global musculoskeletal disorder therapeutics market vendors 2015-2020
Exhibit 40: AbbVie: YoY revenue and growth rate of Humira 2013-2015 ($ billions)
Exhibit 41: AbbVie: Geographical segmentation of Humira 2015
Exhibit 42: AbbVie: Metrics analysis
Exhibit 43: Key products in musculoskeletal disorders market with 2015 revenues
Exhibit 44: Johnson & Johnson: YoY revenue and growth rate of Remicade 2013-2015 ($ billions)
Exhibit 45: Johnson & Johnson: YoY revenue and growth rate of Simponi/Simponi Aria 2013-2015 ($ billions)
Exhibit 46: Johnson & Johnson: YoY revenue and growth rate of Stelara 2013-2015 ($ billions)
Exhibit 47: Johnson & Johnson: Metrics analysis
Exhibit 48: Amgen: YoY revenue and growth rate of Enbrel (US and Canada) 2013-2015 ($ billions)
Exhibit 49: Amgen: YoY revenue and growth rate of Prolia 2013-2015 ($ billions)
Exhibit 50: Amgen: Geographical segmentation of Prolia 2015
Exhibit 51: Amgen: Metrics analysis
Exhibit 52: Key products in musculoskeletal disorders market with 2015 revenues
Exhibit 53: Pfizer: YoY revenue and growth rate of Lyrica 2013-2015 ($ billions)
Exhibit 54: Pfizer: YoY revenue and growth rate of Enbrel (outside US and Canada) 2013-2015 ($ billions)
Exhibit 55: Pfizer: YoY revenue and growth rate of Celebrex 2013-2015 ($ billions)
Exhibit 56: Pfizer: YoY revenue and growth rate of Xeljanz 2013-2015 ($ millions)
Exhibit 57: Pfizer: Metrics analysis
Exhibit 58: F. Hoffmann-La Roche: YoY revenue and growth rate of MabThera/Rituxan 2013-2015 ($ billions)
Exhibit 59: F. Hoffmann-La Roche: Geographical segmentation of MabThera/Rituxan by revenue 2015
Exhibit 60: F. Hoffmann-La Roche: YoY revenue and growth rate of Actemra/RoActemra 2013-2015 ($ billions)
Exhibit 61: F. Hoffmann-La Roche: Geographical segmentation of Actemra/RoActemra by revenue 2015
Exhibit 62: F. Hoffmann-La Roche: Metrics analysis
Exhibit 63: Eli Lilly: YoY revenue and growth rate of Cymbalta 2013-2015 ($ billions)
Exhibit 64: Eli Lilly: YoY revenue and growth rate of Evista 2013-2015 ($ billions)
Exhibit 65: Eli Lilly: Geographical segmentation of Evista 2015
Exhibit 66: Eli Lilly: YoY revenue and growth rate of Forteo 2013-2015 ($ billions)
Exhibit 67: Eli Lilly: Geographical segmentation of Forteo 2015
Exhibit 68: Eli Lilly: Metrics analysis

  • United States Virus Like Particles Market Report 2017
    Published: 12-Oct-2017        Price: US 3800 Onwards        Pages: 107
    In this report, the United States Virus Like Particles market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report splits the United States market into seven regions: - The West - Southwest - The Middle Atlantic - New England - The South - The Midwest with sales (volume), revenue (value), market share and growth rat......
  • Global Virus Like Particles Sales Market Report 2017
    Published: 10-Oct-2017        Price: US 4000 Onwards        Pages: 118
    In this report, the global Virus Like Particles market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (K Pcs), revenue (Million USD), market share and growth rate of Virus Like Particles for these regions, from 2012 to 2022 (forecast), covering - United States - China - Europe - Ja......
  • Heavy Metal Poisoning - Pipeline Review, H2 2017
    Published: 10-Oct-2017        Price: US 2000 Onwards        Pages: 40
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Heavy Metal Poisoning - Pipeline Review, H2 2017, provides an overview of the Heavy Metal Poisoning (Toxicology) pipeline landscape.Heavy metal poisoning is the accumulation of heavy metals, in toxic amounts, in the soft tissues of the body. Sources of toxicity can include environmental, water supply, industrial and hobbies. Symptoms include headaches, drowsiness, confusion, seizures, nausea, vomiting, abdomin......
  • Radiation Injury - Pipeline Review, H2 2017
    Published: 10-Oct-2017        Price: US 2000 Onwards        Pages: 46
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Radiation Injury - Pipeline Review, H2 2017, provides an overview of the Radiation Injury (Toxicology) pipeline landscape.Radiation injury is damage to tissues caused by exposure to ionizing radiation. Symptoms depend on whether radiation exposure involves the whole body or is limited to a small portion of the body. At high doses, whole-body exposure causes acute radiation illness, and partial-body exposure ca......
  • Low Back Pain - Pipeline Review, H2 2017
    Published: 10-Oct-2017        Price: US 2000 Onwards        Pages: 98
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Low Back Pain - Pipeline Review, H2 2017, provides an overview of the Low Back Pain (Central Nervous System) pipeline landscape.Low back pain can happen anywhere below the ribs and above the legs. Causes of low back pain include overuse, strain, or injury, aging, arthritis, illness and cancer involving the spine. Symptoms include tingling or burning sensation, a dull achy feeling, or sharp pain and weakness in......
  • Binge Eating Disorder - Pipeline Review, H2 2017
    Published: 10-Oct-2017        Price: US 2000 Onwards        Pages: 62
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Binge Eating Disorder - Pipeline Review, H2 2017, provides an overview of the Binge Eating Disorder (Central Nervous System) pipeline landscape.Binge eating disorder is a serious condition characterized by uncontrollable eating and resulting weight gain. The causes of binge-eating disorder are unknown. But family history, biological factors, long-term dieting and psychological issues increase your risk. Signs ......
  • Global Microbiome Therapeutics Market Research Report 2017
    Published: 10-Oct-2017        Price: US 2900 Onwards        Pages: 127
    In this report, the global Microbiome Therapeutics market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Microbiome Therapeutics in these regions, from 2012 to 2022 (forecast), covering - North America - Europe - Ch......
  • Global Sexual Dysfunction Partnering 2010 to 2017
    Published: 01-Oct-2017        Price: US 1495 Onwards        Pages: 100
    "Delivery of this report will take 1-3 days after purchase." The Global Sexual Dysfunction Partnering Terms and Agreements since 2010 report provides understanding and access to partnering deals and agreements entered into by the world's leading healthcare companies. • Trends in partnering deals • Top deals by value • Deals listed by company A-Z, industry sector, stage of development, technology type The report provides ......
  • Global Musculoskeletal Partnering 2010-2017: Deal trends, players and financials
    Published: 01-Oct-2017        Price: US 2995 Onwards        Pages: 1000
    "Delivery of this report will take 1-3 days after purchase." Global Musculoskeletal Partnering 2010 to 2017 provides the full collection of Musculoskeletal disease deals signed between the world's pharmaceutical and biotechnology companies since 2010. Trends in Musculoskeletal partnering deals Financial deal terms for headline, upfront and royalty by stage of development Musculoskeletal partnering agreement structure Musculoskel......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs